Jaguar Health, Inc.

Jaguar Health, Inc. announced a special stock dividend of Series R Convertible Preferred Stock to common stockholders and certain warrant holders of record on October 13, 2026. Each Series R share will convert into five common shares on November 2, 2026. The company stated the dividend is intended to reward shareholders and provide dilution protection as it evaluates strategic alternatives. Additionally, Jaguar Health amended royalty interest agreements with Uptown Capital and Streeterville Capital, extending the initiation of monthly payments to January 1, 2027, and extended the maturity date of a secured promissory note with Streeterville to the same date. The company also noted progress in its crofelemer development program for rare intestinal failure diseases.

Jaguar Health, Inc. entered into exchange agreements with Streeterville Capital, LLC, exchanging $5,049,909.26 of its outstanding 2025 Note balance for 547,898 shares of its common stock. This transaction reduces the principal of the 2025 Note and the shares were issued under a registration exemption. The company also reported its total outstanding shares as of September 23, 2026.

Jaguar Health, Inc. will hold a Special Meeting of Stockholders on September 4, 2026, to vote on several key proposals. These include approving the issuance of common stock upon the exchange of Series Q Preferred Stock, which could lead to substantial dilution for existing shareholders, and the repricing of Investor Warrants to a significantly lower exercise price of $1.00 per share. Additionally, shareholders will vote on increasing the shares authorized for the 2014 Stock Incentive Plan to 14% of fully diluted common stock. All proposals require shareholder approval under Nasdaq Listing Rule 5635(d).

Jaguar Health, Inc. filed an S-1 registration statement for the resale of up to 5,522,551 shares of common stock by selling stockholders. These shares are linked to recent financing activities, including a $40 million Equity Line of Credit and a $2 million Series P Preferred Stock financing. The company will not receive any proceeds from the resale of these shares. Additionally, the company recently completed the conversion of Series O Preferred Stock into 4,857,211 common shares.

Jaguar Health's wholly-owned subsidiary, Napo Pharmaceuticals, Inc., entered into a new manufacturing and supply agreement with Alivus Life Sciences Limited. This agreement, signed on July 9, 2026, ensures the continued supply of crofelemer, the active pharmaceutical ingredient for Mytesi®, following the expiration of the previous agreement on March 31, 2026. The new contract extends until March 31, 2029, includes minimum purchase commitments, and outlines various termination provisions.

Jaguar Health completed the conversion of its Series O Convertible Preferred Stock into Common Stock on June 25, 2026. This follows a special one-time dividend of Series O Preferred Stock issued on March 4, 2026, which was retroactively adjusted for a 1-for-35 reverse stock split on April 30, 2026. Each share of Series O Preferred Stock converted into 3.209 shares of Common Stock. Following the conversion, the company has 4,857,211 shares of Common Stock issued and outstanding, with Eligible Warrants entitling holders to receive up to 839,000 additional common shares upon exercise.

Jaguar Health announced the automatic conversion of its Series O Convertible Preferred Stock into common stock at a ratio of 3.209 common shares per preferred share, effective June 25, 2026. This conversion follows the preferred stock being issued as a one-time special stock dividend. Additionally, the company's subsidiary, Napo Pharmaceuticals, amended its Manufacturing and Supply Agreement with Woodward Specialty LLC to clarify inventory management and transfer, ensuring business continuity. Jaguar Health also reiterated its focus on crofelemer development for rare intestinal failure diseases, targeting Breakthrough Therapy designation for MVID and an NDA filing in the first half of 2027.

Jaguar Health's Board of Directors has initiated a process to explore strategic alternatives aimed at maximizing shareholder value. This review is aligned with the anticipated completion of clinical work for a New Drug Application (NDA) filing for its crofelemer-based drug candidate for rare intestinal failure diseases. Potential alternatives include mergers, acquisitions, partnerships, and licensing arrangements. The company emphasizes its commitment to the crofelemer development program, which has shown promising results in clinical trials for conditions like microvillus inclusion disease and short bowel syndrome.

Jaguar Health, Inc. announced that its Board of Directors has initiated a process to explore a range of strategic alternatives aimed at maximizing shareholder value. This exploration aligns with the anticipated completion of clinical work supporting a New Drug Application (NDA) for its crofelemer prescription drug candidate for rare intestinal failure diseases. Potential alternatives include mergers, acquisitions, partnerships, joint ventures, and licensing arrangements. The company highlighted the significant market opportunity for crofelemer, with the microvillus inclusion disease market estimated at $1.1 billion in 2026, projected to reach $1.5 billion by 2033.

Jaguar Health, Inc. has entered into several amendments and exchange agreements primarily with Streeterville Capital, LLC and Uptown Capital, LLC. Key changes include amendments to royalty interest agreements, extending the initiation of monthly royalty payments to October 1, 2026, with a minimum payment of $750,000. Additionally, the maturity date of a $6.22 million promissory note with Streeterville has been extended to October 1, 2026. The company also completed three exchange transactions with Streeterville, issuing a total of 110,249 shares of common stock in exchange for shares of Series Q Preferred Stock.